3-Methyl-5-propylpyrazol | 7231-30-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-Methyl-5-propylpyrazol
• 英文别名: 5-methyl-3-propyl-1H-pyrazole
• CAS: 7231-30-3
• 化学式: C₇H₁₂N₂
• 分子量: 124.186
• InChiKey: KYXQTGAWIVEDFA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-Methyl-5-propylpyrazol 在 potassium permanganate 作用下， 生成 3,5-吡唑二甲酸
  参考文献：
  名称：

  Bertrand, Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences, 1957, vol. 245, p. 2306

  摘要：

  DOI：
• 作为产物：
  描述：

  庚烷-2,4-二酮 在 hydrazine hydrate 作用下， 以 乙醇 为溶剂， 反应 1.0h， 生成 3-Methyl-5-propylpyrazol
  参考文献：
  名称：

  Discovery and SAR Evolution of Pyrazole Azabicyclo[3.2.1]octane Sulfonamides as a Novel Class of Non-Covalent N-Acylethanolamine-Hydrolyzing Acid Amidase (NAAA) Inhibitors for Oral Administration

  摘要：

  DOI：

  10.1021/acs.jmedchem.1c00575

文献信息

• [EN] PYRAZOLE DERIVATIVES WHICH MODULATE STEAROYL-COA DESATURASE<br/>[FR] DÉRIVÉS DE PYRAZOLE QUI MODULENT LA STÉAROYL-COA DÉSATURASE
  申请人：NOVARTIS AG

  公开号：WO2011039358A1

  公开（公告）日：2011-04-07

  The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.

  本发明提供了能够调节硬脂酰辅酶A脱饱和酶活性的杂环衍生物。还涵盖了利用这些衍生物调节硬脂酰辅酶A脱饱和酶活性的方法以及包含这些衍生物的药物组合物。
• Treatment of viral infections by modulation of host cell metabolic pathways
  申请人：Munger Josh

  公开号：US20090239830A1

  公开（公告）日：2009-09-24

  Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated.

  描述了在病毒感染时发生的某些代谢物浓度和通量的改变。选择涉及代谢途径的宿主细胞酶作为干预靶点；即恢复代谢通量以不利于病毒复制，或进一步扰乱代谢通量导致病毒感染细胞的“自杀”（但不包括未感染的细胞），以限制病毒传播。虽然可以选择相关代谢途径中的任何酶，但是在这些代谢途径中关键控制点的关键酶更适合作为候选抗病毒药物靶点。使用这些酶的抑制剂来逆转或重定向病毒感染的影响。使用体外筛选分析和宿主细胞以及动物模型测试药物候选物的抗病毒活性。然后使用动物模型测试候选化合物在预防和治疗病毒感染方面的功效。证明了酶抑制剂的抗病毒活性。
• MULTISUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS
  申请人：VERSEON CORPORATION

  公开号：US20160024047A1

  公开（公告）日：2016-01-28

  There are provided inter alia multisubstituted aromatic compounds useful for the inhibition of kallikrein, which compounds include substituted pyrazolyl or substituted triazolyl. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing certain diseases or disorders, which disease or disorder is amenable to treatment or prevention by the inhibition of kallikrein.

  本发明提供了多取代芳香化合物，其中包括取代的吡唑基或取代的三唑基，用于抑制卡利肽酶，另外还提供了制药组合物。本发明还提供了治疗和预防某些疾病或疾病的方法，该疾病或疾病可通过抑制卡利肽酶来治疗或预防。
• G protein-coupled receptor kinase 2 inhibitors and methods for use of the same
  申请人：THE REGENTS OF THE UNIVERSITY OF MICHIGAN

  公开号：US10023564B2

  公开（公告）日：2018-07-17

  Disclosed herein are novel GRK2 inhibitors and methods for their use in treating or preventing heart disease, such as cardiac failure, cardiac hypertrophy, and hypertension. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salt thereof: wherein the substituents are as described.

  本文公开了新型 GRK2 抑制剂及其用于治疗或预防心脏疾病（如心力衰竭、心脏肥大和高血压）的方法。特别是，本文公开了式(I)化合物及其药学上可接受的盐：其中取代基如所述。
• Bouveault; Bongert, Bulletin de la Societe Chimique de France, 1902, vol. <3> 27, p. 1083,1088, 1089
  作者：Bouveault、Bongert

  DOI：——

  日期：——